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Background: Long-term mortality and causes of death in patients with pulmonary tuberculosis 
(PTB) and extrapulmonary tuberculosis (EPTB) are poorly documented. In this study, long-term 
mortality and causes of death in PTB and EPTB patients were compared with the background 
population and it was investigated whether mortality was associated with family-related risk 
factors.
Methods: A nationwide cohort study was conducted including: all adult Danes notified with PTB 
or EPTB from 1977 to 2008 and alive 1 year after diagnosis; a randomly selected comparison 
cohort matched on birth date and sex; adult siblings of PTB patients; and population controls. 
Data were extracted from national registries. All-cause and cause-specific mortality rate ratios 
were calculated for patients and siblings and compared with their respective control cohorts.   
A total of 8,291 patients (6,402 PTB and 1,889 EPTB), 24,873 population controls, 1,990 siblings 
of PTB patients and 11,679 siblings of PTB population controls were included.
Results: Overall, the mortality rate ratio was 1.86 (95% confidence interval [CI] 1.77–1.96) 
for PTB patients and 1.24 (95% CI 1.12–1.37) for EPTB patients. Both patient cohorts had 
significantly increased risk of death due to infectious diseases and diabetes. Further, the PTB 
patients had increased mortality due to cancers (mainly respiratory and gastrointestinal tract), 
liver and respiratory system diseases, and alcohol and drug abuse. The PTB patients had increased 
mortality compared with their siblings (mortality rate ratio 3.55; 95% CI 2.57–4.91) as did the 
siblings of the PTB patients compared with the siblings of population controls (mortality rate 
ratio 2.16; 95% CI 1.62–2.87).
Conclusion: We conclude that adult PTB patients have an almost two-fold increased long-term 
mortality whereas EPTB patients have a slightly increased long-term mortality compared with 
the background population. The increased long-term mortality in PTB patients stems from 
diseases associated with alcohol, tobacco, and drug abuse as well as immune suppression, and 
family-related factors.
Keywords: pulmonary tuberculosis, extrapulmonary tuberculosis, mortality, causes of death, 
siblings, cohort study
Introduction
Tuberculosis (TB) causes more than 1.4 million deaths annually and is the second 
leading cause of death due to an infectious disease after human immunodeficiency 
virus (HIV).1 The morbidity and mortality associated with TB is especially pronounced 
in low-income developing countries where malnutrition, crowded living conditions, 
and lack of TB control measures makes the disease a serious public health burden.1–3 
In high-income industrialized nations, the epidemiology of TB has changed, with 
immigrants from endemic countries now constituting a major proportion of new Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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TB cases.4,5 Several studies have established specific risk 
factors and predictors of short-term case fatality rates, but 
the long-term prognosis of patients with TB is still poorly 
described.6–8
In order to assess whether long-term mortality is affected 
in patients who have survived a TB episode compared with 
the background population, we conducted a nationwide 
population-based cohort study to determine long-term 
mortality and causes of death in patients diagnosed with 
pulmonary (PTB) or extrapulmonary tuberculosis (EPTB). 
To investigate potential family-related risk factors, we also 
estimated mortality in siblings of the patients with TB.
Materials and methods
Ethics statement
This study is a registry-based cohort study involving data 
from various Danish national registries. All data were anony-
mized before any statistical analysis was performed and the 
study was approved by the Danish Data Protection Agency.
study design
This study was conducted as a population-based nationwide 
cohort study. The study populations were all PTB and EPTB 
patients registered in Denmark in the period 1977–2008 
and a cohort from the background population individually 
matched on age and sex. Outcomes were time to death and 
to cause-specific death. The risk of these outcomes was 
further estimated in the siblings of the patients with TB 
and compared with that of the siblings of the comparison 
cohort.
setting
The population of Denmark was 5.08 million on January 1, 
1977 and 5.48 million on January 1, 2008.9 The incidence of 
TB decreased in the study period from 12/100.000 in 1977 
to 6/100.000 in 2008.10,11 Denmark has an estimated HIV 
prevalence of 0.07%.12 Throughout the study period, Danish 
citizens had access to free health care and antituberculosis 
medication. The Bacille Calmette Guerin vaccine was phased 
out of the Danish national childhood vaccination program 
in the period 1976–1980. All culture-based TB diagnostics 
are centralized at the International Reference Laboratory of 
Mycobacteriology at Statens Serum Institut, Copenhagen, 
Denmark.
Data sources
The unique 10-digit personal identification number assigned 
to all Danish citizens at birth or immigration was used to 
avoid multiple registrations and to track individuals in the 
following registries.
Danish Tuberculosis registry
All TB patients diagnosed in Denmark are notified to the 
  Danish Tuberculosis Registry by the treating physician and by 
the International Reference Laboratory of Mycobacteriology. 
This notification is mandatory for all patients initiating 
anti-TB treatment. The Danish Tuberculosis Registry con-
tains data on anatomical localization of TB, ethnic origin, 
date of diagnosis, residence, and microbiologic data.
Danish national Patient registry
The Danish National Patient Registry (DNPR) contains 
information on all patients discharged from Danish somatic 
hospitals since 1977.13 Data includes dates of admission and 
discharge diagnosis coded by the International Classification 
of Diseases, Eighth Revision (ICD-8), until the end of 1993 
and the Tenth Revision (ICD-10) thereafter. From this 
registry, date of first admission with PTB or EPTB was 
extracted.
Danish Civil registration system
The Danish National Patient Registry (DCRS) was estab-
lished in 1968 and contains information on date and place 
of birth and death, sex, immigration and/or emigration for 
all Danish residents.14
Danish registry of Causes of Death
The Danish Registry of Causes of Death contains data 
from all Danish death certificates since 1943 and is 
updated to December 31, 2009.15 Causes of death are coded 
according to ICD-8 until the end of 1993 and according to 
ICD-10 thereafter. The physician can code one immedi-
ate cause of death followed by secondary and/or tertiary 
causes of death and finally one underlying (main) cause 
of death.
study population
PTB and EPTB patients
We included all individuals who fulfilled the following five 
criteria: notified to the Danish Tuberculosis Registry from 
January 1, 1977 until December 31, 2008; registered in the 
DNPR with a diagnosis of PTB (ICD-8 codes 011.00–013.00 
and ICD-10 codes A15.0–17.0) or EPTB (ICD-8 codes 
014.00–019.00 and ICD-10 codes A 18.0–20.0); notified to 
the Danish Tuberculosis Registry within 1 year of DNPR 
date of discharge; $16 years of age at time of diagnosis; Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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and registered in the DCRS. EPTB was defined as TB of all 
anatomical localizations other than lungs and pleura, with 
the exception of tuberculous meningitis and intracerebral 
tuberculoma (a detailed study of this patient category has 
recently been published by Christensen et al)16 and patients 
diagnosed with miliary TB (to ensure uniform patient 
populations with sole organ involvement). Diagnosis was 
either microbiologically verified by positive culture, nucleic 
acid amplification, or direct microscopy, or based on clini-
cal symptoms and/or radiology. The date of TB diagnosis 
was defined as the date of first admission for TB according 
to DNPR, and the index date as 1 year after TB diagnosis. 
Patients were excluded from the study population if they 
died, emigrated, or were lost to follow-up within the first 
year of TB diagnosis.
Population comparison cohorts
For each TB patient, we identified all Danish citizens 
in the DCRS who were born in Denmark with the same 
birth date and sex as the patient and were alive and not 
diagnosed with TB on the index date of the respective 
patient. From this population, we randomly identified three 
individuals per TB patient who constituted the comparison 
cohort. The index date for the population controls was 
therefore the same as for the TB patient to whom they 
were matched.
siblings
From the DCRS, all siblings of the PTB patients and PTB 
population controls were identified who fulfilled the follow-
ing criteria: full siblings; born after January 1, 1952, and 
alive and not younger than 16 years of age at the time of the 
patient’s or control’s index date. Less than 10% of siblings of 
individuals born before 1952 could be identified in DCRS, 
rising to 43% in the 1952 birth cohort and 96% for individu-
als born after 1958.17 EPTB siblings were not included due 
to inadequate study population size which did not allow for 
sibling mortality studies.
Comorbidity
A modified Charlson Comorbidity Index (CCI) score was 
used as a measurement of comorbidity and calculated from 
DNPR diagnoses prior to the first TB diagnosis.18 Three 
levels of comorbidity were defined: none (CCI score 0), low 
(CCI score 1–2), and high (CCI score .3). As an alterna-
tive measure of comorbidity, data on in-hospital patient 
admissions in the 5 years prior to the date of TB diagnosis 
was extracted from the DNPR for all patients, population 
controls, and siblings. These data were subcategorized 
according to diagnostic categories based on discharge 
diagnosis.
statistical analysis
Time was calculated from index date to the date of death, emigra-
tion, loss to follow-up or December 31, 2009, whichever came 
first. Kaplan–Meier analyses were used to construct survival 
curves. All-cause mortality rate ratios (MRR), representing 
relative risk of death, and 95% confidence intervals (CIs) were 
calculated and stratified according to sex, age at time of diagno-
sis, ethnicity, and level of CCI score of the TB patient. Cause-
specific MRRs were based on the underlying cause of death and 
categorized as listed in the Supplementary materials.
For siblings we computed time from January 1, 1977, or 
the index date of the respective patient or population con-
trol, whichever came last, until date of death, emigration, 
loss to follow-up, or December 31, 2009, whichever came 
first. Poisson regression analyses were used to calculate all-
cause and cause-specific MRRs (adjusted for age and sex) 
for siblings of PTB patients compared with siblings of the 
PTB population controls and for PTB patients born after 
1 January, 1952 compared with their respective siblings. 
Statistical Package for the Social Sciences version 15.0 for 
Windows (SPSS Inc., Chicago, IL, USA), R version 2.13.0 
(R Foundation for Statistical Computing, Vienna, Austria), 
and Stata version 11 (StataCorp, College Station, TX, USA) 
were used for data analysis.
Results
Characteristics of TB patient cohorts
We identified 11,258 TB patients of whom 6,402 PTB 
patients and 1,889 EPTB patients fulfilled the inclusion 
criteria (Figure 1). A total of 5,290 (82.6%) PTB patients 
and 1,713 (90.7%) EPTB patients were microbiologically 
verified. For both cohorts, the proportion of immigrants 
increased with calendar time (Table 1). Due to the study 
design, the control cohorts were well matched with respect 
to age and sex, but PTB and EPTB patients had more comor-
bidity and had been hospitalized more frequently than their 
respective population control cohorts (Table 1).
Characteristics of sibling cohorts
A total of 1,990 siblings of PTB patients and 11,679 siblings 
of the PTB control cohort were identified. The PTB patients’ 
siblings had slightly increased comorbidity, including TB, 
and more were HIV-positive compared with the siblings of 
the population control cohort (Table 1).Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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11,258 patients diagnosed with TB between 1977 and 2008 in Denmark
142 patients with cerebral TB
140 patients with miliary TB
10,976 patients
8,489 PTB patients
1,430 (16.8%) died, emigrated
or LFU within first year of
diagnosis
655 (7.7%) age ≤16 yrs at
time of diagnosis
2 (0.02%) excluded due to
lack of population controls
2,487 EPTB patients
410 (16.5%) died, emigrated or
LFU within first year of diagnosis
188 (7.6%) age ≤16 yrs at time
of diagnosis
EPTB:control
population ratio 1:3
5,667 population controls 1,889 EPTB patients
PTB and EPTB study
populations
Sibling study
population
1,990 siblings of PTB patients
11,679 siblings of PTB population
controls
2,314 (14.3%)
half-siblings
840 (21.8%)
half-siblings
749 (19.4%) age
<16 yrs at
patient’s index
date
1,637 (10.1%) age 
<16 yrs at control’s
index date
602 (3.7%) died,
emigrated of LFU
prior to the control’s
index date
279 (7.2%) died,
emigrated or
LFU prior to the
patient’s index
date
3,858 siblings born after January 1,1952
3,223 patients born after January 1, 1952
1,019 with registered siblings
3,179 patients born
before January
 1, 1952
16,232 siblings born after January 1, 1952
9,669 patients born after January 1, 1952
6,755 with registered siblings
9,537 controls born
before January
1, 1952
19,206 population controls
PTB:control
population ratio 1:3
6,402 PTB patients
Figure 1 summary of study design.
Notes: nationwide cohort study of long-term mortality in patients with TB, Denmark, 1977–2008. 
Abbreviations: EPTB, extrapulmonary tuberculosis; lFU, lost to follow-up; PTB, pulmonary tuberculosis; TB, tuberculosis; yrs, years.
Mortality in PTB patient population 
versus matched population controls
A total of 2,388 (37.3%) PTB patients and 4,683 (24.4%) 
PTB population controls died during the study period. A 
Kaplan–Meier survival curve for the PTB cohort and their 
population control cohort is shown in Figure 2. An overall 
MRR of 1.86 (95% CI 1.77–1.96) was found for the PTB 
cohort (Table 2).
When stratified by individual risk factors, a higher 
mortality was found in the PTB cohort for males (MRR 2.04; 
95% CI 1.92–2.17) compared with females (MRR 1.61; 95% 
CI 1.48–1.75). The MRR decreased with increasing age at time 
of TB diagnosis and the relative risk of death increased with 
increased comorbidity (Table 2). Danish-born PTB patients had 
a slightly higher risk of death (MRR 1.94; 95% CI 1.84–2.04) 
than immigrants (MRR 1.71; 95% CI 1.48–1.98).Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of PTB and EPTB patient cohorts, population comparison cohorts, and sibling cohorts
PTB  
patients
PTB  
population 
controls
Siblings of  
PTB patients
Siblings of  
PTB population  
controls
EPTB  
patients
EPTB  
population  
controls
Total number, n (%) 6,402 (25.0) 19,206 (75.0) 1,990 (14.6) 11,679 (85.4) 1,889 (25.0) 5,667 (75.0)
Males, n (%) 3,855 (60.2) 11,565 (60.2) 1,055 (53.0) 6,244 (53.5) 816 (43.2) 2,448 (43.2)
immigrants, n (%) 2,326 (36.3) 0 405 (20.4) 0 1,242 (65.7) 0
Observation time  
(total), years
64,212 234,484 19,268 12,449 20,339 67,272
Observation time,  
median (iQr), years
8.1 (3.7–14.1) 10.5 (5.5–17.2) 8.3 (4.1–13.3) 9.7 (5.4–14.2) 9.3 (4.8–14.7) 10.4 (5.9–15.8)
Observation time  
(total), years, Danes
40,398 7,291  
Observation time, median  
(iQr), years, Danes
7.8 (3.4–14.2) 9.1 (4.6–16.4)  
Observation time  
(total), years, immigrants
23,814 13,047  
Observation time, median  
(iQr), years, immigrants
8.7 (4.3–13.8) 9.4 (5.0–13.8)  
lost to follow-up during  
study period, n (%)
79 (1.2) 4 (0.01) 7 (0.4) 5 (0.01) 34 (1.8) 2 (0.001)
Emigrated during  
study period, n (%)
281 (4.4) 204 (1.1) 54 (2.7) 198 (1.7) 158 (8.4) 62 (1.1)
age at diagnosis,  
median (iQr), years
42.8 (30.1–58.6) 42.8 (30.1–58.6) 31.7 (25.3–38.4) 31.5 (24.0–38.2) 38.8 (28.9–60.2) 38.8 (28.9–60.2)
age at diagnosis by age intervals, n (%)
  16–30 years 1,570 (24.5) 4,710 (24.5) 889 (44.7) 5,043 (43.2) 540 (28.6) 1,620 (28.6)
  31–60 years 3,357 (52.4) 10,071 (52.4) 1,101 (55.3) 6,636 (56.8) 874 (46.3) 2,622 (46.3)
  .61 years 1,475 (23.0) 4,425 (23.0) 0 0 475 (25.1) 1,425 (25.1)
Patients diagnosed by decade, n (%)
  1977–1986 2,026 (31.6) 6,078 (31.6) 548 (29.0) 1,644 (29.0)
    immigrants, n (%) 383 (18.9) 0 168 (30.7) 0
  1987–1996 1,500 (23.4) 4,500 (23.4) 463 (24.5) 1,389 (24.5)
    immigrants, n (%) 605 (40.3) 0 326 (70.4) 0
  1997–2008 2,876 (44.9) 8,628 (44.9) 878 (46.5) 2,634 (46.5)
    immigrants, n (%) 1,338 (46.5) 0 748 (85.2) 0
age at diagnosis by decade, median (iQr), years
  1977–1986 52.6 (34.7–65.9) 52.6 (34.7–65.9) 57.6 (36.3–70.4) 57.6 (36.3–70.4)
  1987–1996 41.2 (29.7–57.6) 41.2 (29.7–57.6) 36.3 (27.2–60.6) 36.3 (27.2–60.6)
  1997–2008 39.5 (28.9–51.5) 39.5 (28.9–51.5) 34.6 (28.1–46.0) 34.6 (28.1–46.0)
Modified Charlson Comorbidity Index, n (%)
  none (score 0) 5,498 (85.9) 17,744 (92.4) 1,897 (95.3) 11,254 (96.4) 1,680 (88.9) 5,231 (92.3)
  low (score 1–2) 791 (12.4) 1,340 (7.0) 85 (4.3) 385 (3.3) 177 (9.4) 408 (7.2)
  high (score $3) 113 (1.8) 122 (0.6) 8 (0.4) 40 (0.3) 32 (1.7) 28 (0.5)
hospital admission in 5 years prior to TB
Total patients, n (%) 2,677 (41.8) 5,589 (29.1) 660 (33.2) 3,695 (31.6) 871 (46.1) 1,854 (32.7)
  infectious diseases 176 (2.7) 171 (0.9) 55 (2.8) 116 (1.0) 58 (3.1) 59 (1.0)
  Pulmonology 426 (6.7) 403 (2.1) 50 (2.5) 255 (2.2) 61 (3.2) 131 (2.3)
  Endocrinology 133 (2.1) 192 (1.0) 16 (0.8) 82 (0.7) 43 (2.3) 51 (0.9)
  gastroenterology 491 (7.7) 834 (4.3) 77 (3.9) 369 (3.2) 134 (7.1) 246 (4.3)
  Psychiatry 225 (3.5) 116 (0.6) 29 (1.5) 91 (0.8) 9 (0.5) 37 (0.7)
  Cardiovascular 320 (5.0) 824 (4.3) 38 (1.9) 166 (1.4) 88 (4.7) 227 (4.0)
  alcohol-related 152 (2.4) 51 (0.3) 10 (0.5) 24 (0.2) 2 (0.1) 9 (0.2)
  injury or poisoning 677 (10.6) 1,105 (5.8) 158 (7.9) 704 (6.0) 106 (5.6) 306 (5.4)
  neurology 90 (1.4) 167 (0.9) 20 (1.0) 97 (0.8) 20 (1.1) 56 (1.0)
Malignant neoplasm prior  
to study inclusion, n (%)
248 (3.9) 565 (2.9) 17 (0.9) 97 (0.8) 61 (3.2) 190 (3.4)
hiV diagnosis before or  
at time of TB diagnosis, n (%)
107 (1.7) 28 (0.001) 9 (0.5) 14 (0.1) 18 (1.2) 6 (0.001)
Medical history of TB before  
study inclusion, n (%)
0 0 163 (8.2) 17 (0.1) 0 0
Abbreviations: EPTB, extrapulmonary tuberculosis; HIV, human immunodeficiency virus; IQR, interquartile range; PTB, pulmonary tuberculosis; TB, tuberculosis.Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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The PTB patients had an increased risk of death from 
natural causes (infectious, malignant, respiratory, rheu-
matic, liver/pancreatic diseases, and diabetes) and also from 
unnatural causes of death (alcohol and drug abuse, injury, 
and poisoning; Table 3 and Table S1). The increased risk 
of malignant diseases in PTB patients was mainly driven 
by cancers of the respiratory tract, esophagus, breast, and 
hematologic system.
Mortality in EPTB patient population 
versus matched population controls
A total of 515 (27.3%) EPTB patients and 1,379 (24.3%) 
EPTB population controls died during the study period. 
A Kaplan–Meier survival curve for the EPTB cohort and their 
respective population control cohort is shown in Figure 2. 
An overall MRR of 1.24 (95% CI 1.12–1.37) was found for 
the EPTB cohort (Table 2). When stratified by individual 
risk factors, the MRR was found to decrease with increasing 
age at time of TB diagnosis. Also, the MRR increased with 
higher levels of comorbidity. The relative risk of death was 
not found to differ significantly when data were stratified by 
sex and ethnicity. The EPTB patients had an increased risk 
of death due to infectious, gastrointestinal, and genitourinary 
diseases, diabetes, and gastrointestinal and hematologic 
neoplasms (Table 3 and Table S1).
Mortality in PTB patient population 
versus their siblings
Compared with their respective siblings, the PTB patients 
had a significantly increased relative risk of death (MRR 
3.55; 95% CI 2.57–4.91). In the stratified analyses we 
observed an increased risk of death in all subgroups 
(Table 2). As all siblings were born after January 1, 1952, 
for comparison we calculated MRR for PTB patients born 
in the same period compared with their respective control 
cohort (MRR 4.62; 95% CI 3.85–5.57). Compared with their 
siblings, the PTB patients were at increased risk of death 
from infectious diseases (MRR 10.56; 95% CI 2.33–47.83), 
malignant neoplasms (MRR 2.71; 95% CI 1.15–6.37), and 
cardiovascular, respiratory, and gastrointestinal diseases 
(Table 3).
Mortality in siblings of PTB patient 
population versus siblings of PTB  
control population
The siblings of the PTB patients had a more than two-
fold excess mortality compared with siblings of the PTB 
control cohort (Table 2), and this was not substantially 
reduced after exclusion of siblings with a history of TB 
(MRR 1.99; 95% CI 1.48–2.69), data not shown in tables. 
In the stratified analyses, an increased relative risk of 
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Figure 2 Kaplan–Meier survival curves.
Notes: graphs depict long-term mortality in patients (dashed line) with PTB (A), and EPTB (B), compared with population controls (solid line), Denmark, 1977–2008.
Abbreviations: EPTB, extrapulmonary tuberculosis; PTB, pulmonary tuberculosis.Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
411
long-term mortality in patients with tuberculosis
death (MRR 2.45; 95% CI 1.76–3.40) was found for male 
siblings of PTB patients compared with male siblings of 
PTB controls.
Compared with siblings of the population controls, the 
siblings of the PTB patients had a significantly increased 
risk of death from infectious diseases (MRR 10.53; 95% 
CI 1.76–63.00), mental disorders, including alcohol and/
or drug abuse (MRR 4.66; 95% CI 2.90–10.37), and 
gastrointestinal diseases (MRR 4.17; 95% CI 1.82–9.53, 
Table 3).
Discussion
In this nationwide, population-based cohort study, we 
observed an almost two-fold increased long-term mortality 
in PTB patients compared with an age-matched and sex-
matched population comparison cohort. Increased relative 
risk of death was mainly predicted by male sex, younger 
age, native citizenship, comorbidity, and HIV coinfection. 
Further, an increased mortality was observed in the siblings 
of PTB patients. An increased risk of death was also identi-
fied in EPTB patients, although smaller than for the PTB 
patients.
To our knowledge, this is the first study to investi-
gate long-term mortality in TB patients in a nationwide, 
population-based, cohort study design including estimates 
of mortality in siblings of TB patients. Our study has several 
strengths. First, the centralized registration of TB patients 
in Denmark enabled us to identify a large cohort of TB 
patients over a more than 30-year period. Second, having 
a purely native Danish population control cohort excludes 
the possible confounding related to a mixed ethnic control 
cohort. Third, the high proportion of microbiologically 
verified TB cases minimized risk of misclassification. 
Fourth, the extracted data originated from Danish national 
registries with high coverage and long-term and complete 
follow-up, thus providing high validity. Finally, access to 
the Danish registries allowed us to generate well matched, 
population-based comparison cohorts and identify siblings 
of the patients and population comparison cohorts. We were 
not able to adjust for potential confounding from smoking, 
alcohol abuse, and socioeconomic factors which may partly 
explain the observed excess mortality. We did not have 
access to patient files and were therefore not able to account 
for clinical parameters and treatment regimes. Also, our 
results are derived from a high-income setting with a low 
incidence of TB and HIV, and may not be comparable with 
settings of developing nations with a high incidence of HIV 
and drug-resistant TB.
Several studies have identified age, male sex, comorbidity, 
diabetes, HIV , and native citizenship as risk factors for active 
TB and short-term mortality in TB patients.19,20 We identified 
the same factors, except age, to be risk factors for increased 
long-term relative risk of death. The relative risk of death 
was highest in the younger age categories which may seem 
counterintuitive, but reflects the fact that the absolute risk 
of death is highest in the older background population, and 
increased mortality in the older TB patients thereby leads to 
a minor impact on relative risk of death.
Both PTB and EPTB patients were at increased risk of 
death due to TB, which is in accordance with a study from 
the UK which found TB to be responsible for 21% of all 
deaths during a 14-year follow-up.20 Both our cohorts were 
also at increased risk of death due to diabetes, a disease 
associated with not only an increased risk of TB but also 
increased mortality in TB patients; two retrospective US 
cohort studies both reported more than a six-fold increased 
mortality in diabetic TB patients compared with nondia-
betic controls.21,22 With increasing use of biologic disease-
modifying antirheumatic drugs, patients with rheumatic 
diseases are at increased risk of TB infection;23 this is 
reflected in our results, with PTB patients exhibiting more 
than a two-fold increased risk of death due to underlying 
rheumatic disease.
The epidemiologic evidence that alcohol abuse and 
exposure to cigarette smoke increase the risk of active TB 
is strong.24,25 The prevalence of alcohol abuse disorders 
among TB patients in developed countries ranges from 
10% to 50%,26–30 and it has been estimated that almost one 
third of Danish PTB patients suffer from alcohol abuse 
and one in ten from drug abuse.31,32 This is supported in 
our data on in-hospital admissions in the 5 years prior 
to TB diagnosis, where admissions linked to alcohol 
abuse were significantly more frequent among the PTB 
patients compared with population controls. Further, 
lower socioeconomic status is associated with active 
transmission of TB among native Danes.33 We observed 
an increased risk of long-term mortality in PTB patients 
from chronic lung diseases and lung cancer, alcohol and 
drug abuse, and gastrointestinal diseases, particularly 
liver-related. Also, the risk of death was increased in the 
siblings of these patients. Our data thereby underlines 
the fact that conditions related to tobacco, alcohol and 
drug abuse, immune suppression, and socioeconomic 
factors are not only risk factors for contracting TB and 
short-term mortality, but also are main determinants of 
long-term mortality.Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
412
Christensen et al
Table 2 all-cause mortality rate ratios in PTB and EPTB patients, population controls, and siblings, Denmark, 1977–2008
PTB cohort EPTB cohort Siblings (n=1,990) of PTB patients versus siblings  
(n=11,679) of PTB controls; all born after January 1, 1952
PTB patients (n=1,019) versus their respective siblings 
(n=1,990); all born after January 1, 1952
Number of  
patients who  
died
Number of  
controls who  
died
MRR 
 (95% CI)
Number of  
patients  
who died
Number of  
controls  
who died
MRR  
(95% CI)
Number of  
siblings of patients  
who died (%)
Number of  
siblings of controls  
who died (%)
MRR  
(95% CI)a
Number of  
patients  
who died (%)
Number of  
siblings of patients  
who died (%)
MRR  
(95% CI)a
Overall 2,388 (37.3%) 4,683 (24.4%) 1.86 (1.77–1.96) 515 (27.3%) 1,379 (24.3%) 1.24 (1.12–1.37) 74 (3.7) 206 (1.8) 2.16 (1.62–2.87) 110 (10.8) 74 (3.7) 3.55 (2.57–4.91)
Overall for individuals  
born after January 1, 1952
271 (8.4) 193 (2.0) 4.62 (3.85–5.57)  
MRR stratified on individual risk factors 
sex  
  Females 812 1,757 1.61 (1.48–1.75) 299 789 1.24 (1.09–1.42) 16 65 1.53 (0.86–2.73) 30 16 6.95 (3.46–13.94)
  Males 1,576 2,926 2.04 (1.92–2.17) 216 590 1.23 (1.05–1.43) 58 141 2.45 (1.76–3.40) 80 58 2.86 (1.98–4.12)
age at diagnosis (years)  
  16–30 87 106 2.71 (2.04–3.59) 16 20 2.61 (1.35–5.04) 21 68 2.09 (1.27–3.44) 29 21 2.93 (1.63–5.28)
      0–10 years  
observation time
12 18 2.19 (1.05–4.55) 5 4 4.09 (1.10–15.25)  
     . 10 years  
observation time
0 1 n/a 0 0 n/a  
  31–60 1,104 1,464 2.80 (2.59–3.03) 140 310 1.50 (1.23–1.83) 53 138 2.17 (1.54–3.08) 81 53 3.88 (2.63–5.72)
      0–10 years  
observation time
500 306 5.87 (5.09–6.77) 36 73 1.64 (1.10–2.44)  
     . 10 years  
observation time
184 198 3.44 (2.81–4.20) 20 29 2.39 (1.35–4.22)  
 . 60 1,197 3,113 1.57 (1.47–1.68) 359 1,049 1.15 (1.02–1.29) 0 0 n/a 0 0 n/a
     0–10 years  
observation time
1,079 2,032 2.23 (2.07–2.40) 266 680 1.32 (1.14–1.52)  
      . 10 years  
observation time
613 2,128 1.38 (1.26–1.50) 188 593 1.15 (0.98–1.36)  
Ethnicity  
  native Danes 2,119 4,147 1.94 (1.84–2.04) 429 1,158 1.27 (1.13–1.42) 72 206 2.38 (1.78–3.18) 105 72 3.45 (2.48–4.80)
  immigrantsb 269 536 1.71 (1.48–1.98) 86 221 1.26 (0.98–1.62) 2 0 n/a 5 2 5.85 (1.12–30.61)
Modified Charlson  
Comorbidity index
 
  score 0 1,857 3,689 1.80 (1.70–1.90) 407 1,119 1.18 (1.06–1.33)  
  score 1 460 902 2.20 (1.96–2.46) 90 234 1.46 (1.15–1.86)  
  score 2 71 92 4.22 (3.09–5.75) 18 26 3.11 (1.70–5.67)            
Notes: aadjusted for sex and age; bimmigrant patients compared with their Danish population controls. 
Abbreviations: CI, confidence interval; EPTB, extrapulmonary tuberculosis; MRR, mortality rate ratio; n/a, not applicable; PTB, pulmonary tuberculosis.
Compared with PTB patients, we observed only minor 
increased risk of death in the EPTB patients, which supports 
previous results of lower case fatality rates among patients 
with EPTB.19 Also, the findings point toward less impact from 
tobacco, alcohol, and drug abuse.
We found a significantly increased risk of death due to 
malignant neoplasms in the PTB patient group compared with 
population controls. This excess mortality was primarily driven 
by an increased prevalence of deaths due to cancers of the air-
ways, esophagus, breast and hematopoietic system. The major-
ity of these subcategories have been strongly associated with 
smoking, alcohol abuse, and immunodeficiency.34–39 A recent 
population-based cohort study from Taiwan that included 
5,657 TB patients and 23,984 controls found a statistically 
significant increased incidence of lung cancer in the years after 
TB infection (269 per 100,000 person-years) compared with 
population controls (153 per 100,000 person-years).40
The siblings of the PTB patients were at markedly increased 
risk of death compared with the siblings of the population 
controls and appeared to be at increased risk of death due to 
infectious and gastrointestinal diseases and alcohol and drug 
abuse. This high excess mortality among the siblings of PTB 
patients indicates that the excess long-term mortality among 
PTB patients cannot solely be attributed to an effect of TB infec-
tion, but must also be influenced by other family-associated, 
behavioral, and/or socioeconomic-related factors. We presume Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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Table 2 all-cause mortality rate ratios in PTB and EPTB patients, population controls, and siblings, Denmark, 1977–2008
PTB cohort EPTB cohort Siblings (n=1,990) of PTB patients versus siblings  
(n=11,679) of PTB controls; all born after January 1, 1952
PTB patients (n=1,019) versus their respective siblings 
(n=1,990); all born after January 1, 1952
Number of  
patients who  
died
Number of  
controls who  
died
MRR 
 (95% CI)
Number of  
patients  
who died
Number of  
controls  
who died
MRR  
(95% CI)
Number of  
siblings of patients  
who died (%)
Number of  
siblings of controls  
who died (%)
MRR  
(95% CI)a
Number of  
patients  
who died (%)
Number of  
siblings of patients  
who died (%)
MRR  
(95% CI)a
Overall 2,388 (37.3%) 4,683 (24.4%) 1.86 (1.77–1.96) 515 (27.3%) 1,379 (24.3%) 1.24 (1.12–1.37) 74 (3.7) 206 (1.8) 2.16 (1.62–2.87) 110 (10.8) 74 (3.7) 3.55 (2.57–4.91)
Overall for individuals  
born after January 1, 1952
271 (8.4) 193 (2.0) 4.62 (3.85–5.57)  
MRR stratified on individual risk factors 
sex  
  Females 812 1,757 1.61 (1.48–1.75) 299 789 1.24 (1.09–1.42) 16 65 1.53 (0.86–2.73) 30 16 6.95 (3.46–13.94)
  Males 1,576 2,926 2.04 (1.92–2.17) 216 590 1.23 (1.05–1.43) 58 141 2.45 (1.76–3.40) 80 58 2.86 (1.98–4.12)
age at diagnosis (years)  
  16–30 87 106 2.71 (2.04–3.59) 16 20 2.61 (1.35–5.04) 21 68 2.09 (1.27–3.44) 29 21 2.93 (1.63–5.28)
      0–10 years  
observation time
12 18 2.19 (1.05–4.55) 5 4 4.09 (1.10–15.25)  
     . 10 years  
observation time
0 1 n/a 0 0 n/a  
  31–60 1,104 1,464 2.80 (2.59–3.03) 140 310 1.50 (1.23–1.83) 53 138 2.17 (1.54–3.08) 81 53 3.88 (2.63–5.72)
      0–10 years  
observation time
500 306 5.87 (5.09–6.77) 36 73 1.64 (1.10–2.44)  
     . 10 years  
observation time
184 198 3.44 (2.81–4.20) 20 29 2.39 (1.35–4.22)  
 . 60 1,197 3,113 1.57 (1.47–1.68) 359 1,049 1.15 (1.02–1.29) 0 0 n/a 0 0 n/a
     0–10 years  
observation time
1,079 2,032 2.23 (2.07–2.40) 266 680 1.32 (1.14–1.52)  
      . 10 years  
observation time
613 2,128 1.38 (1.26–1.50) 188 593 1.15 (0.98–1.36)  
Ethnicity  
  native Danes 2,119 4,147 1.94 (1.84–2.04) 429 1,158 1.27 (1.13–1.42) 72 206 2.38 (1.78–3.18) 105 72 3.45 (2.48–4.80)
  immigrantsb 269 536 1.71 (1.48–1.98) 86 221 1.26 (0.98–1.62) 2 0 n/a 5 2 5.85 (1.12–30.61)
Modified Charlson  
Comorbidity index
 
  score 0 1,857 3,689 1.80 (1.70–1.90) 407 1,119 1.18 (1.06–1.33)  
  score 1 460 902 2.20 (1.96–2.46) 90 234 1.46 (1.15–1.86)  
  score 2 71 92 4.22 (3.09–5.75) 18 26 3.11 (1.70–5.67)            
Notes: aadjusted for sex and age; bimmigrant patients compared with their Danish population controls. 
Abbreviations: CI, confidence interval; EPTB, extrapulmonary tuberculosis; MRR, mortality rate ratio; n/a, not applicable; PTB, pulmonary tuberculosis.
that these associations are explained by the fact that alcohol and 
drug abuse clusters in families and also leads to increased risk 
of TB as well as death due to infectious and gastrointestinal 
diseases. However, the MRR of PTB patients born after January 
1, 1952 was almost twice that of their siblings, indicating that 
specific risk factors are also present in the PTB patient cohort 
and increase their mortality, although part of this excess mortal-
ity can be reflected in the younger age of the siblings. Studies 
have shown that growing up in an environment of low socioeco-
nomic status increases the risk of death later in life;41,42 hence, 
one explanation might be that the patients and siblings share the 
same low socioeconomic status during childhood and are thus at 
increased risk of death in adulthood. Genetic predisposition to 
death from infectious diseases43 has been proposed along with 
evidence of increased genetic host susceptibility to acquiring 
infectious diseases such as TB.44–47
Our study has several clinical implications. It emphasizes 
that, in high-income settings, PTB patients suffer from sub-
stantially increased long-term mortality compared with EPTB 
patients and compared with the background population. 
  Furthermore, it establishes that classical risk factors for active 
TB and short-term mortality are also the main risk factors 
for long-term mortality, and that PTB patients are at a sig-
nificantly increased risk of dying from conditions related to 
tobacco, alcohol, and drug abuse and immune suppression. 
The study underlines the importance of addressing lifestyle Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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Table 3 Cause-specific mortality rate ratios in PTB and EPTB patients, population controls, and siblings, Denmark, 1977–2008
PTB cohort EPTB cohort Siblings of PTB patients versus siblings of PTB controls PTB patients versus their respective siblings
Number of  
patients  
who died  
(n=2,388)
Number of  
controls  
who died  
(n=4,683)
MRR 95% CI Number of  
patients  
who died  
(n=515)
Number  
of controls  
who died  
(n=1,379)
MRR 95% CI Number of  
siblings of patients  
who died  
(n=74 total)
Number of  
siblings of controls  
who died  
(n=206 total)
MRRa 95% CI Number of  
patients  
who died  
(n=110 total)
Number of  
siblings of  
patients who  
died (n=74 total)
MRRa 95% CI
infectious diseases 156 31 18.38 12.50–27.02 14 8 5.79 2.43–13.80 7 2 10.53 1.76–63.00 11 7 10.56 2.33–47.83
neoplasmsb 530 1,242 1.56 1.41–1.73 118 334 1.17 0.95–1.44 13 54 1.32 0.67–2.61 13 13 2.71 1.15–6.37
    Malignant neoplasms of lip,  
oral cavity, and pharynx
28 22 4.65 2.66–8.12 0 7  
    Malignant neoplasms of  
digestive organs
128 349 1.34 1.10–1.65 34 72 1.56 1.04–2.35  
    Malignant neoplasms of  
respiratory and intrathoracic  
organs
191 303 2.30 1.92–2.76 25 72 1.15 0.73–1.81  
    Malignant neoplasms of  
bone and articular cartilage
1 3 1.22 0.13–11.70 1 1  
    Melanoma and other  
malignant neoplasms of skin
3 17 0.64 0.19–2.20 1 7 0.47 0.06–3.84  
  Malignant neoplasms of breast 27 63 1.57 1.00–2.46 10 23 1.44 0.68–3.02  
    Malignant neoplasms  
of female genital organs
13 57 0.83 0.46–1.52 5 31 0.53 0.21–1.37  
    Malignant neoplasms  
of male genital organs
24 100 0.88 0.56–1.37 7 20 1.16 0.49–2.74  
    Malignant neoplasms  
of urinary tract
21 74 1.04 0.64–1.68 5 28 0.59 0.23–1.53  
    Malignant neoplasms  
of central nervous system
7 32 0.80 0.35–1.81 2 4  
    Malignant neoplasms of thyroid  
and other endocrine organs
0 3 1 0  
    Malignant hematologic  
neoplasms
37 87 1.55 1.06–2.28 15 25 1.98 1.05–3.76  
    Malignant neoplasm of other  
and ill-defined sites
50 125 1.46 1.05–2.03 10 43 0.75 0.38–1.49  
  Benign neoplasms 0 7     2 1                    
hematologic diseases 10 15 2.43 1.09–5.42 1 3 1.10 0.11–10.60 0 3 1 0
Endocrine diseases 67 123 1.99 1.48–2.68 17 35 1.61 0.90–2.87 1 4 1.76 0.20–15.75 3 1 5.41 0.56–52.29
Psychiatric disorders  
(including those caused by  
alcohol and/or drug abuse)
108 142 2.78 2.16–3.57 8 27 0.98 0.45–2.16 12 15 4.66 2.09–10.37 11 12 2.44 0.97–6.09
neurologic diseases 21 73 1.05 0.65–1.71 9 14 2.13 0.92–4.91 0 6 1 0
Cardiovascular diseases 573 1,761 1.19 1.08–1.31 191 582 1.09 0.92–1.28 5 26 1.35 0.52–3.52 11 5 3.87 1.34–11.21
respiratory diseases 353 432 2.98 2.59–3.43 40 141 0.94 0.66–1.33 3 5 1.40 0.16–11.95 7 3 15.37 1.87–126.61
gastrointestinal diseases 178 210 3.10 2.53–3.78 27 43 2.08 1.28–3.36 10 17 4.17 1.82–9.53 25 10 6.49 2.80–15.05
Dermatologic diseases 0 2 2 2 3.31 0.47–23.48 0 0 0 0
rheumatologic diseases 12 17 2.58 1.23–5.40 1 8 0.41 0.05–3.31 0 0 1 0
genitourinary diseases 22 78 1.03 0.64–1.65 12 16 2.48 1.17–5.24 0 1 0 0
injury or poisoning 150 219 2.50 2.03–3.08 27 72 1.24 0.80–1.93 12 54 1.57 0.84–2.93 14 12 2.00 0.92–4.32
Not classified elsewhere 155 244 2.32 1.90–2.84) 32 79 1.34 0.89–2.02 0 9 8 0
Unknown 51 89 2.09 1.48–2.95 14 15 3.09 1.49–6.40 11 7 11.06 4.29–28.52 3 11 0.47 0.13–1.70
Congenital cause of death 2 5 1 0 0 3 1 0
Pregnancy-related death 0 0 1 0 0 0 0 0
Note: aadjusted for sex and age. bDetailed neoplasm subanalysis not performed for sibling study populations due to small case numbers.
Abbreviations: CI, confidence interval; EPTB, extra-pulmonary tuberculosis; MRR, mortality rate ratio; PTB, pulmonary tuberculosis.Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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Table 3 Cause-specific mortality rate ratios in PTB and EPTB patients, population controls, and siblings, Denmark, 1977–2008
PTB cohort EPTB cohort Siblings of PTB patients versus siblings of PTB controls PTB patients versus their respective siblings
Number of  
patients  
who died  
(n=2,388)
Number of  
controls  
who died  
(n=4,683)
MRR 95% CI Number of  
patients  
who died  
(n=515)
Number  
of controls  
who died  
(n=1,379)
MRR 95% CI Number of  
siblings of patients  
who died  
(n=74 total)
Number of  
siblings of controls  
who died  
(n=206 total)
MRRa 95% CI Number of  
patients  
who died  
(n=110 total)
Number of  
siblings of  
patients who  
died (n=74 total)
MRRa 95% CI
infectious diseases 156 31 18.38 12.50–27.02 14 8 5.79 2.43–13.80 7 2 10.53 1.76–63.00 11 7 10.56 2.33–47.83
neoplasmsb 530 1,242 1.56 1.41–1.73 118 334 1.17 0.95–1.44 13 54 1.32 0.67–2.61 13 13 2.71 1.15–6.37
    Malignant neoplasms of lip,  
oral cavity, and pharynx
28 22 4.65 2.66–8.12 0 7  
    Malignant neoplasms of  
digestive organs
128 349 1.34 1.10–1.65 34 72 1.56 1.04–2.35  
    Malignant neoplasms of  
respiratory and intrathoracic  
organs
191 303 2.30 1.92–2.76 25 72 1.15 0.73–1.81  
    Malignant neoplasms of  
bone and articular cartilage
1 3 1.22 0.13–11.70 1 1  
    Melanoma and other  
malignant neoplasms of skin
3 17 0.64 0.19–2.20 1 7 0.47 0.06–3.84  
  Malignant neoplasms of breast 27 63 1.57 1.00–2.46 10 23 1.44 0.68–3.02  
    Malignant neoplasms  
of female genital organs
13 57 0.83 0.46–1.52 5 31 0.53 0.21–1.37  
    Malignant neoplasms  
of male genital organs
24 100 0.88 0.56–1.37 7 20 1.16 0.49–2.74  
    Malignant neoplasms  
of urinary tract
21 74 1.04 0.64–1.68 5 28 0.59 0.23–1.53  
    Malignant neoplasms  
of central nervous system
7 32 0.80 0.35–1.81 2 4  
    Malignant neoplasms of thyroid  
and other endocrine organs
0 3 1 0  
    Malignant hematologic  
neoplasms
37 87 1.55 1.06–2.28 15 25 1.98 1.05–3.76  
    Malignant neoplasm of other  
and ill-defined sites
50 125 1.46 1.05–2.03 10 43 0.75 0.38–1.49  
  Benign neoplasms 0 7     2 1                    
hematologic diseases 10 15 2.43 1.09–5.42 1 3 1.10 0.11–10.60 0 3 1 0
Endocrine diseases 67 123 1.99 1.48–2.68 17 35 1.61 0.90–2.87 1 4 1.76 0.20–15.75 3 1 5.41 0.56–52.29
Psychiatric disorders  
(including those caused by  
alcohol and/or drug abuse)
108 142 2.78 2.16–3.57 8 27 0.98 0.45–2.16 12 15 4.66 2.09–10.37 11 12 2.44 0.97–6.09
neurologic diseases 21 73 1.05 0.65–1.71 9 14 2.13 0.92–4.91 0 6 1 0
Cardiovascular diseases 573 1,761 1.19 1.08–1.31 191 582 1.09 0.92–1.28 5 26 1.35 0.52–3.52 11 5 3.87 1.34–11.21
respiratory diseases 353 432 2.98 2.59–3.43 40 141 0.94 0.66–1.33 3 5 1.40 0.16–11.95 7 3 15.37 1.87–126.61
gastrointestinal diseases 178 210 3.10 2.53–3.78 27 43 2.08 1.28–3.36 10 17 4.17 1.82–9.53 25 10 6.49 2.80–15.05
Dermatologic diseases 0 2 2 2 3.31 0.47–23.48 0 0 0 0
rheumatologic diseases 12 17 2.58 1.23–5.40 1 8 0.41 0.05–3.31 0 0 1 0
genitourinary diseases 22 78 1.03 0.64–1.65 12 16 2.48 1.17–5.24 0 1 0 0
injury or poisoning 150 219 2.50 2.03–3.08 27 72 1.24 0.80–1.93 12 54 1.57 0.84–2.93 14 12 2.00 0.92–4.32
Not classified elsewhere 155 244 2.32 1.90–2.84) 32 79 1.34 0.89–2.02 0 9 8 0
Unknown 51 89 2.09 1.48–2.95 14 15 3.09 1.49–6.40 11 7 11.06 4.29–28.52 3 11 0.47 0.13–1.70
Congenital cause of death 2 5 1 0 0 3 1 0
Pregnancy-related death 0 0 1 0 0 0 0 0
Note: aadjusted for sex and age. bDetailed neoplasm subanalysis not performed for sibling study populations due to small case numbers.
Abbreviations: CI, confidence interval; EPTB, extra-pulmonary tuberculosis; MRR, mortality rate ratio; PTB, pulmonary tuberculosis.Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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and socioeconomic risk factors to substantially reduce long-
term mortality in PTB patients.
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Supplementary materials
Detailed subcategorization of causes of 
death according to iCD-8 and iCD-10 
diagnosis codes
The 18 categories of specific underlying causes of death 
were specified by the International Classification of Diseases,   
Eighth Revision (ICD-8), codes for the years 1977–1993 and 
the International Classification of Diseases, Tenth Revision 
(ICD-10), codes for 1994–2006. For infectious diseases, the 
codes were 000–134.99/A00–B99; cancer 140–209/C00–C96; 
blood/immune diseases 280–289.99/D50–D89; endocrine dis-
eases 240–279.09/E00–E90; mental and   behavioral   disorders, 
including those due to psychoactive substance use and 
inebriation 290–315/F00–F99; nervous system diseases 320–
358.09/G00–G99; diseases of the sensory organs 360–389.99/
H00–H59; cardiovascular diseases 390–458.99/I00–I99; 
respiratory diseases 460–519.99/J00–J99; digestive system 
diseases 520–577.99/K00–K93; skin diseases 680–709.99/
L00–L99; rheumatic diseases 710–738.09/M00–M99; geni-
tourinary diseases 580–629.99/N00–N99; neonatal/congenital 
disorders 740–779.99/P00–Q99; pregnancy-related diseases 
630–678.09/O00–O99; injury/poisoning 800–999/S00–T98, 
V , W, X, Y; ill-defined causes 780–796.99/R00–R99; and no 
cause of death reported.Clinical Epidemiology 2014:6 submit your manuscript | www.dovepress.com
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long-term mortality in patients with tuberculosis